EUCTR2004-001605-10-IT进行中（未招募）不适用
A Phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors GISTs resistant to imatinib mesylate
ISTITUTO NAZIONALE PER LA CURA TUMORI0 个研究点目标入组 15 人开始时间: 2007年3月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
2 期
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to ImatinibSarcomaNCT00117299University of Helsinki45
终止
2 期
PTK787 in Refractory or Relapsed Diffuse Large Cell LymphomaLymphoma, Large-Cell, DiffuseNCT00511043David Rizzieri, MD20
进行中（未招募）
不适用
A dose-finding study of PTK787/ZK 222584 in combination with weekly vinorelbine and trastuzumab as treatment of patients with metastatic breast cancer overexpressing HER-2/neu pre-treated withy at least one line of chemotherapy. - NDMedDRA version: 6.1Level: SOCClassification code 10038604EUCTR2005-005669-12-ITAZIENDA OSPEDALIERA S. FILIPPO NERI18
进行中（未招募）
2 期
A study of tucatinib (MK-7119) in combination with trastuzumab and capecitabine in participants with previously treated locally advanced unresectable or metastatic human epidermal growth factor receptor 2 positive (HER2+) breast carcinoma (MK-7119-001)Previously treated locally advanced unresectable or metastatic HER2+ breast carcinomaJPRN-jRCT2051200152akamura Sosuke55
终止
2 期
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple MyelomaMultiple MyelomaNCT00240162Washington University School of Medicine21